A phase 2 study of E6005 in patients with atopic dermatitis
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-jRCT2080221633
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 75
Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained
- Outpatients diagnosed with atopic dermatitis
- Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen disorder or Netherton's syndrome, etc., which could have an effect on the pathological evaluation of the atopic dermatitis.
- Patients with active infection that requires oral or intravenous administration of antibiotics, antifungal or antivirus agent/s at baseline.
- Patients with advanced disease or abnormal laboratory tests that would possibly affect the safety of the subject or the implementation of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Assessment of safety parameters: number and variety of adverse events, clinical laboratory test<br>- Assessment of efficacy variable: Pruritus score, area and severity of eczema
- Secondary Outcome Measures
Name Time Method